X4 Pharmaceuticals Updates Principal Executive Offices
Ticker: XFOR · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: administrative, corporate-action
TL;DR
X4 Pharma moved offices to Boston, MA.
AI Summary
On March 3, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134. The company's former name was Arsanis, Inc., with a name change effective September 20, 2010.
Why It Matters
This filing signals a physical relocation for X4 Pharmaceuticals, Inc., which could impact operational logistics and employee location.
Risk Assessment
Risk Level: low — This filing is administrative and does not involve financial or operational changes that would inherently increase risk.
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- Arsanis, Inc. (company) — Former company name
- March 3, 2025 (date) — Date of report
- 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 (location) — New principal executive offices
- September 20, 2010 (date) — Date of name change
FAQ
What is the new address for X4 Pharmaceuticals, Inc.'s principal executive offices?
The new address is 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.
When was the report filed?
The report was filed on March 3, 2025.
What was X4 Pharmaceuticals, Inc.'s former name?
X4 Pharmaceuticals, Inc.'s former name was Arsanis, Inc.
When did the company change its name from Arsanis, Inc.?
The name change was effective on September 20, 2010.
What is the state of incorporation for X4 Pharmaceuticals, Inc.?
The state of incorporation is Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding X4 Pharmaceuticals, Inc (XFOR).